You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY20 is not expected to be complete until September, 2021.

  1. New heterocyclic inhibitors of filoviruses

    SBC: MICROBIOTIX, INC.            Topic: H

    DESCRIPTION provided by applicant Ebola and Marburg viruses belong to the family Filoviridae and can cause fatal hemorrhagic fevers characterized by widespread tissue destruction with an incubation period of days Because of the safety concerns these viruses are designated as the biosafety level agents Currently there is no effective vaccine or therapeutic treatment against filoviral i ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  2. New small molecule inhibitors of arenaviruses

    SBC: MICROBIOTIX, INC.            Topic: R

    DESCRIPTION provided by applicant Lassa fever virus LASV and Machupo virus MACV are hemorrhagic fever arenaviruses which are classified as Category A Agents Currently there are no licensed LASV or MACV vaccines and LASV MACV therapy is limited to use of the nucleoside analog ribavirin which is only partially effective and associated with significant side effects The impact of arenavirus ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  3. Rapid Immunodiagnosis of Drug-Resistant Bacterial Pathogens

    SBC: SILVER LAKE RESEARCH CORPORATION            Topic: NIAID

    DESCRIPTION provided by applicant Bacterial resistance to lactam antibiotics is threatening to limit the effectiveness of this most used class of antibiotics A major contributin factor to this problem is the lack of rapid testing methods for medical practitioners to identify lactam resistant pathogens before prescribing specific antibiotics For urinary tract infections UTIs the most c ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  4. RAP as a therapeutic compound for neuronal regeneration after spinal cord injury

    SBC: Novoron Bioscience Inc.            Topic: 101

    DESCRIPTION provided by applicant RAP as a therapeutic compound for neuronal regeneration after spinal cord injury Novoron Bioscience Inc RESEARCH andamp RELATED Other Project Information Project Summary There are an estimated to new cases of spinal cord injury SCI each year and million people in the United States are paralyzed in some form due to SCI Currently ther ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  5. Optimized lactoferrin for treatment of intracerebral hemorrhage

    SBC: Pharmareview Corporation            Topic: NINDS

    DESCRIPTION provided by applicant Intracerebral hemorrhage ICH is a major public health problem with highest mortality rate of all stroke subtypes and long term disability Since there are no available FDA approved therapies for ICH it is of enormous importance to establish effective treatment for this medical condition Following ICH the deposited blood is damaging initially via compression ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  6. Development of Peptide Antibiotic Nucleic Acids

    SBC: NUBAD, LLC            Topic: NIAID

    DESCRIPTION provided by applicant One of the challenges of research in infectious diseases is to find ways to use the increasing knowledge of the mechanisms underlying disease transformation and progression to develop novel therapeutic strategies for diseases such as increasing menace of bacterial infections Targeting specific RNA such as rRNA which are involved in proliferation and survival ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  7. A molecularly targeted pre- and post-exposure vaccine for anthrax

    SBC: VLP BIOTECH, INC.            Topic: NIAID

    DESCRIPTION provided by applicant We have shown that immunization of rabbits with multiple antigenic peptides MAPs displaying sequence from domain of protective antigen PA elicit antibodies specific for a linear determinant within the loop of PA that mediate potent neutralization of lethal toxin LeTx in vitro We have now shown in two separate large studies that antibodies aga ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  8. Anti-Pseudomonas Immunotherapy and Targeted Drug Delivery

    SBC: SORRENTO THERAPEUTICS, INC.            Topic: NIAID

    DESCRIPTION provided by applicant Antibody therapy for serious bacterial infections using polyclonal immune antitoxin or anti capsule horse serum actually predates small molecule antibiotic use However for reasons of safety convenient empirical use and cost the development of broader spectrum antibiotics rapidly supplanted the use of immune serum But drug resistance is quickly reducing th ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  9. Low-Cost Instrument-free Point-of-care Platform for Multiplexed Chlamydia Diagnos

    SBC: Lucira Health, Inc.            Topic: NIAID

    DESCRIPTION provided by applicant Detecting Chlamydia Ct STIs at the point of care POC represents a critical unmet medical need Development of an effective Ct POC diagnostic will result in widespread screening efforts for rapid diagnosis to inform treatment and evaluate treatment efficacy and for test of cure that would not only reduce the acute and chronic morbidity that is directly asso ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  10. Ovarian cancer using novel nanoparticle formulations

    SBC: Kiromic BioPharma, Inc.            Topic: 102

    DESCRIPTION provided by applicant Ovarian cancer is the fifth most leading cause of cancer related deaths in women in the US It has been observed that the cancer relapses within relatively short periods of time even after the surgery and chemotherapy Therefore immunotherapeutic strategies may serve as an alternative to control the recurrence or progression of ovarian cancer Oral vaccines ar ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government